Biomea Fusion is trading 5.87% up now at $1.90, following a broader biotechnology-sector advance rather than a confirmed company-specific catalyst.
- Biotech ETF XBI is up 2.55% during regular trading, supported by stronger pharmaceutical and biotech demand, improving research funding, and renewed M&A optimism.
- The latest identified Biomea Fusion announcement was its September 3 investor-conference notice; no new major company release was identified for September 18.